Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lumos: rhNGF in Retinitis Pigmentosa
NCT02110225Phase 2Completed
- Sponsor
- Dompé
- Start
- Jan 2014
- Primary completion
- Nov 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of cenegermin in retinitis pigmentosa (RP) (3 arms), sponsored by Dompé. Primary endpoints: Number of Participants With Serious and Non-Serious Adverse Events at 48 weeks, Change in Ocular Tolerability - VAS at 24 weeks and 6 more. Started Jan 2014; status: completed.
02
Drugs
cenegermin
03
Conditions
retinitis pigmentosa (RP)
Beyond the preview
Go deeper on NCT02110225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02110225.